Safety profile of RNAi nanomedicines - PubMed

Affiliations

• PMID: 22732527
• DOI: 10.1016/j.addr.2012.06.007

Review

Safety profile of RNAi nanomedicines

Scott A Barros et al. Adv Drug Deliv Rev. 2012 Dec.

Abstract

The emerging class of RNA interference (RNAi) therapeutics is a fundamentally novel approach to treating human disease by enabling the pursuit of molecular targets considered "undruggable" by small molecules and traditional protein therapeutics. A key challenge toward realizing the full potential of this technology is the safe and efficient delivery of siRNA to target tissues. The physical chemical properties of siRNAs preclude passive diffusion across most cell membranes. For systemic administration, novel delivery systems are required to confer "drug-like" pharmacokinetic and pharmacodynamic properties. Engineered nanomaterials and the emerging field of nanomedicine are important drivers of turning the promise of RNAi therapeutics into reality. The current clinical progress of systemically administered siRNA therapeutics is reviewed, with special attention to the toxicity profiles associated with RNAi nanomedicines. As a case study, the preclinical development of ALN-VSP, the first lipid nanoparticle (LNP)-formulated siRNA therapeutic to be tested in cancer patients, is reviewed to broadly highlight some of the preclinical safety challenges and areas of investigation for "next generation" LNP systems.

Similar articles

• Lipid-based nanoparticles for siRNA delivery in cancer therapy: paradigms and challenges.

  Gomes-da-Silva LC, Fonseca NA, Moura V, Pedroso de Lima MC, Simões S, Moreira JN. Gomes-da-Silva LC, et al. Acc Chem Res. 2012 Jul 17;45(7):1163-71. doi: 10.1021/ar300048p. Epub 2012 May 8. Acc Chem Res. 2012. PMID: 22568781

• RNAi nanomedicines: challenges and opportunities within the immune system.

  Weinstein S, Peer D. Weinstein S, et al. Nanotechnology. 2010 Jun 11;21(23):232001. doi: 10.1088/0957-4484/21/23/232001. Epub 2010 May 13. Nanotechnology. 2010. PMID: 20463388 Review.

• First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement.

  Tabernero J, Shapiro GI, LoRusso PM, Cervantes A, Schwartz GK, Weiss GJ, Paz-Ares L, Cho DC, Infante JR, Alsina M, Gounder MM, Falzone R, Harrop J, White AC, Toudjarska I, Bumcrot D, Meyers RE, Hinkle G, Svrzikapa N, Hutabarat RM, Clausen VA, Cehelsky J, Nochur SV, Gamba-Vitalo C, Vaishnaw AK, Sah DW, Gollob JA, Burris HA 3rd. Tabernero J, et al. Cancer Discov. 2013 Apr;3(4):406-17. doi: 10.1158/2159-8290.CD-12-0429. Epub 2013 Jan 28. Cancer Discov. 2013. PMID: 23358650 Clinical Trial.

• Delivery of RNAi therapeutics: work in progress.

  Miller AD. Miller AD. Expert Rev Med Devices. 2013 Nov;10(6):781-811. doi: 10.1586/17434440.2013.855471. Expert Rev Med Devices. 2013. PMID: 24195461 Review.

• RNAi-based nanomedicines for targeted personalized therapy.

  Daka A, Peer D. Daka A, et al. Adv Drug Deliv Rev. 2012 Oct;64(13):1508-21. doi: 10.1016/j.addr.2012.08.014. Epub 2012 Sep 5. Adv Drug Deliv Rev. 2012. PMID: 22975009 Review.

Cited by

• RNA-Based Therapeutics: Current Developments in Targeted Molecular Therapy of Triple-Negative Breast Cancer.

  Haque S, Cook K, Sahay G, Sun C. Haque S, et al. Pharmaceutics. 2021 Oct 15;13(10):1694. doi: 10.3390/pharmaceutics13101694. Pharmaceutics. 2021. PMID: 34683988 Free PMC article. Review.

• Non-viral vectors for RNA delivery.

  Yan Y, Liu XY, Lu A, Wang XY, Jiang LX, Wang JC. Yan Y, et al. J Control Release. 2022 Feb;342:241-279. doi: 10.1016/j.jconrel.2022.01.008. Epub 2022 Jan 10. J Control Release. 2022. PMID: 35016918 Free PMC article. Review.

• Epigenetic Targets for Oligonucleotide Therapies of Pulmonary Arterial Hypertension.

  Gerthoffer W. Gerthoffer W. Int J Mol Sci. 2020 Dec 3;21(23):9222. doi: 10.3390/ijms21239222. Int J Mol Sci. 2020. PMID: 33287230 Free PMC article. Review.

• Lipid-Based Nanocarriers for RNA Delivery.

  Xue HY, Guo P, Wen WC, Wong HL. Xue HY, et al. Curr Pharm Des. 2015;21(22):3140-7. doi: 10.2174/1381612821666150531164540. Curr Pharm Des. 2015. PMID: 26027572 Free PMC article. Review.

• Design of siRNA Therapeutics from the Molecular Scale.

  Angart P, Vocelle D, Chan C, Walton SP. Angart P, et al. Pharmaceuticals (Basel). 2013;6(4):440-68. doi: 10.3390/ph6040440. Pharmaceuticals (Basel). 2013. PMID: 23976875 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Elsevier Science
  • Ovid Technologies, Inc.

• Other Literature Sources

  • The Lens - Patent Citations Database

• Research Materials

  • NCI CPTC Antibody Characterization Program